QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.05 USD
-0.92 (-2.19%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $41.04 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
What's in the Cards for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
Quidel (QDEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Quidel (QDEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Quidel (QDEL) Looks Good: Stock Adds 10.8% in Session
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Earnings Preview: Quidel (QDEL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 7.69% and 0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (QDEL) Q2 Earnings Meet Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 0.00% and 0.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Products Industry Outlook: Growth Prospects Radiant
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
QDEL vs. BAX: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. BAX: Which Stock Is the Better Value Option?
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
by Zacks Equity Research
Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
by Zacks Equity Research
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
Here's Why You Should Retain HMS Holdings (HMSY) Stock
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
4 Top Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Invest in DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
by Zacks Equity Research
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.